Viewing Study NCT07215832

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:57 PM
Ignite Modification Date: 2026-01-02 @ 9:52 AM
Study NCT ID: NCT07215832
Status: AVAILABLE
Last Update Posted: 2025-10-14
First Post: 2025-09-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Karyopharm Expanded Access Program for Selinexor
Sponsor: Karyopharm Therapeutics Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
None Diffuse Large B-Cell Lymphoma (DLBCL) View
None Sarcoma View
None Neuroglioblastoma View
None Peripheral T-cell Lymphoma View
None Endometrial Cancer View
None Myelofibrosis View
None Other View
Keywords:

Keywords

Keyword Brief Keyword Text View
None selinexor View